29.73
-0.42
(-1.41%)
As of 3:04:22 PM EST. Market Open.
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 3,000 | 3 |
| Sales | 1,353,455 | 5 |
| Net Shares Purchased (Sold) | -1,350,455 | 8 |
| Total Insider Shares Held | 4.24M | -- |
| % Net Shares Purchased (Sold) | -24.10% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| POST LEONARD E Director | Sale at price 29.66 per share. | Direct | 29,660 | Jan 13, 2025 |
| POST LEONARD E Director | Conversion of Exercise of derivative security at price 0.60 per share. | Direct | 600 | Jan 13, 2025 |
| POST LEONARD E Director | Sale at price 28.84 per share. | Direct | 28,840 | Dec 16, 2024 |
| POST LEONARD E Director | Conversion of Exercise of derivative security at price 0.60 per share. | Direct | 600 | Dec 16, 2024 |
| SONG HONG FANG Director | Sale at price 28.00 per share. | Indirect | 19,600,000 | Dec 16, 2024 |
| POST LEONARD E Director | Sale at price 34.40 - 34.98 per share. | Direct | 34,542 | Dec 6, 2024 |
| POST LEONARD E Director | Conversion of Exercise of derivative security at price 0.60 per share. | Direct | 600 | Dec 6, 2024 |
| SONG HONG FANG Director | Sale at price 35.36 per share. | Indirect | 23,000,089 | Aug 29, 2024 |
| DECHENG CAPITAL GLOBAL LIFE SCIENCES FUND IV, L.P. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 37.00 per share. | Indirect | 14,800,000 | Jan 29, 2024 |
| DECHENG CAPITAL GLOBAL LIFE SCIENCES FUND IV, L.P. Beneficial Owner of more than 10% of a Class of Security | -- | Direct | -- | Jan 29, 2024 |
| ROCHE CORLEEN M Chief Financial Officer | Purchase at price 37.00 per share. | Direct | 74,000 | Jan 29, 2024 |
| SONG HONG FANG Director | Purchase at price 37.00 per share. | Direct | 9,736,809 | Jan 29, 2024 |
| SONG HONG FANG Director | -- | Indirect | -- | Jan 29, 2024 |
| KASTURI VIJAY M.D. Officer | Purchase at price 37.00 per share. | Direct | 48,655 | Jan 29, 2024 |
| DECHENG VENTURE CAPITAL LTD. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 37.00 per share. | Indirect | 29,600,000 | Jan 29, 2024 |
| DECHENG VENTURE CAPITAL LTD. Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Jan 29, 2024 |
Related Tickers
AVBP ArriVent BioPharma, Inc.
28.53
-1.93%
BCAX Bicara Therapeutics Inc.
12.77
-1.08%
MBX MBX Biosciences, Inc.
10.40
-10.65%
APGE Apogee Therapeutics, Inc.
41.28
-2.88%
KYTX Kyverna Therapeutics, Inc.
3.2400
-2.11%
LXEO Lexeo Therapeutics, Inc.
5.42
+3.24%
ALMS Alumis Inc.
7.41
+10.26%
ZBIO Zenas BioPharma, Inc.
8.00
+4.99%
CGEM Cullinan Therapeutics, Inc.
10.53
-4.10%
ARTV Artiva Biotherapeutics, Inc.
5.05
-6.48%